Agios Pharmaceuticals, Inc.
58 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
4
Ending by 2030
Jun 2030
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 18, 2027The maintenance fee for Therapeutic Compounds and Compositions (US RE49,582) comes due Jan 18, 2027. Unpaid by Jul 19, 2027, it lapses early.
- 1 fee due Feb 18, 2027The maintenance fee for Therapeutic compounds and compositions (US 9,108,921) comes due Feb 18, 2027. Unpaid by Aug 18, 2027, it lapses early.
- 1 fee due Apr 24, 2027The maintenance fee for Pyruvate Kinase Activators for Use in Therapy (US 11,793,806) comes due Apr 24, 2027. Unpaid by Oct 25, 2027, it lapses early.
- 1 fee due May 24, 2027The maintenance fee for Pyruvate Kinase Activators for Use in Therapy (US 9,193,701) comes due May 24, 2027. Unpaid by Nov 24, 2027, it lapses early.
- 1 fee due Jun 1, 2027The maintenance fee for Therapeutic Compounds and Compositions (US 9,199,968) comes due Jun 1, 2027. Unpaid by Dec 1, 2027, it lapses early.
- 3 fees due Jul 9 to 23, 2027 · next Jul 9
- 1 fee due Sep 5, 2027The maintenance fee for Compounds and Methods Useful for Stabilizing Phenylalanine Hydroxylase Mutations (US 11,919,915) comes due Sep 5, 2027. Unpaid by Mar 6, 2028, it lapses early.
- 2 fees due Oct 16 to 28, 2027 · next Oct 16
Recent changes
- 1 term has ended since Aug 18, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,029,987 | Therapeutic Compounds and Compositions In force · Medium confidence | In force | Medium confidence | |
| US 10,988,448 | Therapeutic Compounds and Compositions In force · Medium confidence | In force | Medium confidence | |
| US 12,428,376 | Therapeutic Compounds and Compositions In force · Medium confidence | In force | Medium confidence | |
| US 11,866,411 | Therapeutic Compounds and Compositions In force · Medium confidence | In force | Medium confidence | |
| US 8,889,667 | Therapeutic Compounds and Compositions In force · High confidence | In force | High confidence | |
| US 9,199,968 | Therapeutic Compounds and Compositions In force · High confidence | In force | High confidence | |
| US 9,682,080 | Pyruvate Kinase Activators for Use in Therapy In force · High confidence | In force | High confidence | |
| US 9,980,961 | Pyruvate Kinase Activators for Use in Therapy In force · Medium confidence | In force | Medium confidence | |
| US 10,632,114 | Pyruvate Kinase Activators for Use in Therapy In force · Medium confidence | In force | Medium confidence | |
| US 12,377,093 | Pyruvate Kinase Activators for Use in Therapy In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 32: 58 patents in force now held by others · 27 lapsed for an unpaid fee · 2 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
11 pending · 20 abandoned · 25 no status recorded